Wesper Announces $9.6 Million Series A Round

Wesper, the first clinical-grade FDA-cleared wireless home sleep lab, announced a $9.6 million Series A round to accelerate growth and revenue as well as continue to develop industry-leading diagnostic sensing technology. The round included participation from Valor Equity Partners, Breyer Capital, Spark Capital, as well as angel investors from leading health-tech firms.

Wesper’s wireless biometric sensors and algorithms enable at-home medical diagnosis with professional services and ongoing measurement before, during, and after treatment. With Wesper, users have access to customized, professional guidance from sleep specialists and physicians without having to leave their homes.

“Wesper is at the forefront of revolutionizing the sleep industry through superior access to biometric data and an increased focus on patient experience, working to ensure that every patient who suffers from sleep problems gets the care they deserve,” said Amir Reuveny, Founder and CEO of Wesper.

With this new funding round, Wesper will build partnerships with sleep centers, dental clinics and coaches to bring Wesper to patients across the US. Through FDA clearance for assistance with HSAT (home sleep apnea testing), clinics can use Wesper’s superior algorithms, biometric data, and unparalleled patient experience to help more patients.

The company has on-boarded key medical institutions and is set to expand its presence in the sleep clinic space. This includes expanding its medical advisor network and forging strategic partnerships with key players such as hospitals, sleep labs, and insurance providers.

“Improving your sleep used to be a very lonely and complicated process, and we are here to change that,” says Dr. Chelsie Rohrscheib, the head sleep expert at Wesper. “We are committed to our users every step of the way to getting high-quality sleep.”

SourceWesper
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors. 

By using this website you agree to accept Medical Device News Magazine Privacy Policy